Crysvita

Crysvita (burosumab) is a subcutaneous injection used to manage conditions related to phosphate metabolism. This medication is designed to help regulate phosphate levels in the body, supporting bone health and overall well-being.

Crysvita is primarily used to treat conditions associated with elevated phosphate levels, such as X-linked hypophosphatemia. This medication works by binding to fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate levels. By inhibiting FGF23, Crysvita helps to increase phosphate reabsorption in the kidneys, promoting better bone health and reducing symptoms related to phosphate deficiency.

Common effects of Crysvita may include injection site reactions, such as redness, swelling, or pain. Some individuals might experience headaches, fatigue, or mild gastrointestinal discomfort. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Crysvita should be used with caution in individuals with a history of hypersensitivity to burosumab or any of its components. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Regular monitoring of phosphate levels may be necessary to ensure the medication's effectiveness and safety.

Crysvita may interact with other medications, particularly those that affect phosphate metabolism or bone health. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions. Alcohol and certain foods may also affect the absorption and effectiveness of Crysvita.